著者

Tsutomu Ogata Toshiaki Tanaka Masayo Kagami

出版者

The Japanese Society for Pediatric Endocrinology

雑誌

Clinical Pediatric Endocrinology (ISSN:09185739)

巻号頁・発行日

vol.16, no.4, pp.85-87, 2007 (Released:2007-11-17)

参考文献数

6

被引用文献数

7 16

---

In 1990, we proposed the equations to calculate target height (TH) and target range (TR) for Japanese, taking account of the positive height secular trend observed over the last ~100 years. However, height difference between generations appears to have become small or negligible in contemporary Japanese populations. Thus, we re-analyzed the Japanese height data, and revised the equations for TH and TR for contemporary Japanese children as follows (cm): Boys, TH = {PH + (MH + 13)} 2, TR = TH ± 9; and Girls, TH = {(PH - 13) + MH} 2; TR = TH ± 8, where PH indicates paternal height and MH maternal height.

著者

Katsuyuki Nakamura Toshiaki Tanaka Naoya Masumori Atsushi Miyamoto Takeshi Hirano

出版者

The Pharmaceutical Society of Japan

雑誌

Biological and Pharmaceutical Bulletin (ISSN:09186158)

巻号頁・発行日

vol.43, no.10, pp.1506-1510, 2020-10-01 (Released:2020-10-01)

参考文献数

24

被引用文献数

7

---

The usefulness of the urine protein : creatine ratio (UPCR) in management of molecular targeted therapy and immunotherapy has not been studied, although urine protein dipstick testing (uPr) is widely used in the clinical setting. The aim of this study was to investigate the usefulness of UPCR as compared to uPr in patients undergoing molecular targeted therapy for advanced renal cell carcinoma (RCC). A total of 25 patients (median age 68 years) with advanced RCC were included. Sunitinib, pazopanib, axitinib, sorefenib, everolimus, and nivolumab were administered to 15, 9, 16, 3, 7, and 13 patients, respectively, with duplication. Proteinuria was managed according to the grade determined by UPCR. Data at every treatment visit were retrospectively collected and uPr and UPCR were compared. The overall incidences of any grade of proteinuria associated with sunitinib, pazopanib, axitinib, sorafenib and everolimus were 86.7, 88.9, 93.8, 100, and 85.7%, respectively. There were discordances between the uPr-based grade and UPCR-based grade. UPCR did not meet the criteria of Grade 3 in 70.6, 100, 83.3, and 83.3% at visits in cases with uPr 3+ for sunitinib, pazopanib, sorafenib, and everolimus, respectively. In axitinib treatment, UPCR did not meet the criteria for withholding in 46.2% of the cases of uPr 2+ and more. Our study suggests that UPCR may be useful tool in management of adverse events associated with tyrosine kinase inhibitors, everolimus and can provide patients with optimal opportunities for receiving treatment.

著者

Tomohiro Saito Katsuhiko Tachibana Akira Shimatsu Noriyuki Katsumata Naomi Hizuka Kenji Fujieda Susumu Yokoya Toshiaki Tanaka

出版者

The Japanese Society for Pediatric Endocrinology

雑誌

Clinical Pediatric Endocrinology (ISSN:09185739)

巻号頁・発行日

vol.15, no.3, pp.79-84, 2006 (Released:2006-08-02)

参考文献数

8

被引用文献数

1 3

---

Accurate and reliable determination of blood growth hormone level is essential in the diagnosis and treatment of short stature children. However, measured levels differed considerably among measurement kits available in Japan until 2003. Therefore, standardization of the measured values was attempted by measuring growth hormone levels in a sample of healthy adult individuals every year using the different kits. A standardization equation was developed for each kit through linear structural relationship with the mean values of the used kits and measured values in each kit as random variables. A Pearson's correlation coefficient between the mean values of all kits and the measured values from each kit was also obtained. Sources for the marked discrepancies amongst the measured values in the different kits were also explored. The obtained values for slopes and intercepts in the equations varied considerably, but the standard values obtained from these equations after the measured values for each kit were transformed into standard values served well as the standard. The standard solutions in the respective measurement kits were found to be the source of variability in the measured values among the kits.

著者

Maiko Osaka Tomonori Kishino Tsuyoshi Urata Yoko Ida Hideaki Mori Naohiro Kawamura Toshiaki Tanaka Shohei Shibasaki Masayuki Yotsukura Takashi Watanabe Hiroaki Ohnishi

出版者

Japanese Society of Laboratory Medicine

雑誌

Laboratory Medicine International (ISSN:24368660)

巻号頁・発行日

vol.2, no.2, pp.30-38, 2023 (Released:2023-09-27)

参考文献数

33

---

Introduction: Patients with non-alcoholic fatty liver disease (NAFLD) often demonstrate liver injury, as reflected by an elevated serum level of alanine aminotransferase (ALT). This study examined whether the presence of liver injury could be predicted based on findings from conventional sonography. Methods: Subjects were 81 adult female NAFLD patients (mean age, 62 ± 14 years). Defining liver injury as ALT levels >30 IU/L, sonographic findings were compared between patients with and without liver injury. In turn, ALT levels and liver size (defined as the sum of the length of the right lobe [R1+R2] and left lobe [L1+L2] were compared among the three classical grades of fatty liver by sonography. Results: Grade 3 fatty liver, deep attenuation, and hepatomegaly demonstrated relatively high odds ratios for the presence of liver injury. Median L1+L2 and R1+R2+L1+L2 were significantly longer in patients with liver injury (164 mm [interquartile range, 149–178 mm] and 289 mm [267–314 mm]) than in those without (147 mm [130–156 mm] and 260 mm [247–281 mm], respectively; p <0.001 each). ALT levels, L1+L2, and R1+R2+L1+L2 increased with increasing fatty liver grade. Conclusion: The present study suggests that grade 3 fatty liver, deep attenuation and/or hepatomegaly allow easy, non-invasive prediction of the presence of liver injury in elderly women with NAFLD using conventional sonography.

著者

TOSHIAKI TANAKA YOSHIKI SEINO KENJI FUJIEDA YUTAKA IGARASHI SUSUMU YOKOYA KATSUHIKO TACHIBANA YUNOSUKE OGAWA

出版者

The Japan Endocrine Society

雑誌

Endocrine Journal (ISSN:09188959)

巻号頁・発行日

vol.46, no.4, pp.605-612, 1999 (Released:2006-11-25)

参考文献数

20

被引用文献数

4 5

---

To evaluate pharmacokinetics of growth hormone (GH) and its effects on IGF-I, glucose, insulin, nonesterified fatty acid (NEFA) and riglyceride (TG), fifteen Japanese healthy adult male volunteers (20-27 years old) were studied. The subjects were divided into three groups, and received with a single s.c. injection of 0.075, 0.15 and 0.30IU/kg of GH, respectively. The subjects assigned to receive 0.30IU/kg were administered for additional 6 days. After a single administration of GH, Cmax and AUC of GH were increased in a dose-dependent manner. There was a significant positive correlation between the AUC and the T1/2 (r=0.516, P<0.05). Total body clearance was significantly greater in 0.075IU/kg group than the other groups and showed a significant negative correlation with Cmax (r=-0.694, P<0.005) and AUC (r=-0.723, P<0.005). After a single administration of each dose, serum IGF-I concentrations were increased gradually. In the repeated administered group (0.30IU/kg), IGF-I concentrations almost reached a plateau at a significantly high level four days after the start of administration and remained at a high level (786-405.4ng/ml) until day 8. There was no significant difference in diurnal change of blood glucose and serum insulin after a single administration of GH among three groups. In the 0.3U/kg group, there was no significant difference in diurnal change of blood glucose between day 1 and day 7, but serum insulin level was significantly higher in day 7 than in day 1 (P<0.01). Serum concentrations of NEFA were increased over time after administration in all subjects administered once or repeatedly. TG concentrations showed no changes after single administration of each dose level, but were significantly increased on day 7 in the subjects repeatedly treated with 0.30 IU/kg/day. This effect is speculated to be caused by high dose GH treatment. The above findings demonstrated that higher GH dose significantly influences on carbohydrate and lipid metablism. It remains necessary to elucidate what kinds of effects of the long-lasting increased levels of insulin and triglyceride, even if reversible, would have on glucose and lipid metabolism.

著者

Atsushi Hattori Yuko Katoh-Fukui Akie Nakamura Keiko Matsubara Tsutomu Kamimaki Hiroyuki Tanaka Sumito Dateki Masanori Adachi Koji Muroya Shinobu Yoshida Shinobu Ida Marie Mitani Keisuke Nagasaki Tsutomu Ogata Erina Suzuki Kenichiro Hata Kazuhiko Nakabayashi Yoichi Matsubara Satoshi Narumi Toshiaki Tanaka Maki Fukami

出版者

(社)日本内分泌学会

雑誌

Endocrine Journal (ISSN:09188959)

巻号頁・発行日

pp.EJ17-0150, (Released:2017-08-03)

被引用文献数

39

---

Although mutations in ACAN, FGFR3, NPR2, and SHOX typically lead to skeletal dysplasia, and mutations in GHRHR, GH1, GHR, STAT5B, IGF1, IGFALS, and IGF1R usually underlie hormonal defects of the growth hormone (GH)-insulin-like growth factor 1 (IGF1) axis, such mutations have also been identified in patients with idiopathic short stature (ISS). Of these, SHOX abnormalities are known to account for a certain percentage of ISS cases, whereas the frequency of mutations in the other 10 genes in ISS cohorts remains unknown. Here, we performed next-generation sequencing-based mutation screening of the 10 genes in 86 unrelated Japanese ISS patients without SHOX abnormalities. We searched for rare protein-altering variants. The functional significance of the identified variants was assessed by in silico analyses. Consequently, we identified 18 heterozygous rare variants in 19 patients, including four probable damaging variants in ACAN, six pathogenicity-unknown variants in FGFR3, GHRHR, GHR, and IGFALS, and eight possible benign variants. Pathogenic variants in NPR2, GH1, and IGF1 were absent from our cohort. Unlike previously reported patients with ACAN mutations, our four patients with ACAN variants manifested non-specific short stature with age-appropriate or mildly delayed bone ages, and had parents of normal stature. These results indicate that ACAN mutations can underlie ISS without characteristic skeletal features, and that such mutations are possibly associated with de novo occurrence or low penetrance. In addition, our data imply that mutations in FGFR3, NPR2, and GH-IGF1 axis genes play only limited roles in the etiology of ISS.

著者

TERUO SASATOMI YOSHIAKI TSUJI TOSHIAKI TANAKA HIROYUKI HORIUCHI SHIN HYODO KIYOAKI TAKEUCHI OSAMU NAKASHIMA KAZUO SHIROUZU

出版者

久留米大学医学部

雑誌

The Kurume Medical Journal (ISSN:00235679)

巻号頁・発行日

vol.47, no.2, pp.165-168, 2000-06-15 (Released:2009-08-11)

参考文献数

21

被引用文献数

5 9

---

Schwann cell tumor occurring in the intestines is rare . A 68-year-old female came to our hospital because of hematemesis. Barium enema and colonoscopic examination revealed submucosal tumor in the sigmoid colon. Laboratory data showed mild anemia . No other abnormal finding was found in the blood chemistry. Tumor marker levels of carcinoembryonic antigen (CEA), CA19-9, alpha feto protein (AFP) and neuron specific enolase (NSE) were within normal limits. The exploratory laparotomy confirmed a large sigmoid colon tumor. She received sigmoid colectomy. The resected specimen was a submucosal tumor with central depression, measuring 4.7×3.5×3.0cm in size. The cut surface of the tumor was yellowish hue with necrosis. Histological examination showed spindle-shaped tumor cells with palisading comma-shaped nuclei and the nuclear pleomorphism. Immunohistochemical examination revealed that the tumor was positive for S-100 protein staining, and negative for Actin and for H.H.F. staining. These findings showed that this tumor was of Schwann cell origin. We report here the case in detail of a schwannoma in the sigmoid colon.

著者

Akira Shimatsu Noriyuki Iwamoto Toshiaki Tanaka Akira Teramoto Masanori Taketsuna Katsuichiro Ihara Jumpei Funai Minoru Irie Kazuo Chihara

出版者

(社)日本内分泌学会

雑誌

Endocrine Journal (ISSN:09188959)

巻号頁・発行日

vol.62, no.8, pp.749-756, 2015 (Released:2015-08-29)

参考文献数

27

---

In addition to impaired physical activity, adult GH deficiency (GHD) can decrease quality of life (QOL). Hence, assessment of QOL is important to evaluate the efficacy of GH replacement therapy. This study aimed to identify factors that may be predictive of long-term improvement in QOL among clinical/laboratory variables during GH replacement therapy. The analysis included 83 Japanese adults with GHD who participated in the Hypopituitary Control and Complications Study (HypoCCS). Correlations between the change from baseline in clinical/laboratory variables at 6 months and the change from baseline in Quality of life (Short-Form 36 [SF-36] component scores) at 12 months were examined. Unexpectedly, all component scores were negatively correlated with the change in fasting plasma glucose concentration (FPG) (physical component summary [PCS], r = -0.456; mental component summary [MCS], r = -0.523; role/social component summary [RCS], r = -0.433). The change in MCS was positively correlated with the change in insulin-like growth factor-1 standard deviation score (IGF-1 SDS) (r = 0.417). The change in PCS was positively correlated with the change in body fat (r = 0.551). The change in RCS was positively correlated with the change in waist circumference (r = 0.528). Short-term changes in several clinical/laboratory variables, most notably FPG and IGF-1 SDS, were correlated with long-term changes in QOL. The clinical importance of these correlations for predicting GH replacement treatment efficacy warrants further investigation.